BOULDER, Colo.--(BUSINESS WIRE)--May. 16, 2012--
Array BioPharma Inc. (NASDAQ: ARRY) today announced oral presentations
on its two MEK inhibitors, selumetinib (AZD6244) and MEK162 at the 2012
American Society of Clinical Oncology (ASCO) Annual Meeting, which will
held June 1-5, 2012 at McCormick Place in Chicago, Illinois. Array
invented selumetinib and MEK162 and subsequently licensed them to
AstraZeneca and Novartis, respectively.
Three oral presentations at ASCO:
Selumetinib
|
Title:
|
|
|
|
|
|
Phase II double-blind, randomized study of selumetinib (SEL) plus
docetaxel (DOC) versus DOC plus placebo as second-line treatment
for advanced KRAS mutant non-small cell lung cancer (NSCLC) (Abstract
#7503)
|
|
Presenter:
|
|
|
|
|
|
Pasi A. Janne, MD, PhD
|
|
Date:
|
|
|
|
|
|
Monday, June 4, 2012, 5:00 – 5:15 p.m. EDT
|
|
|
|
Title:
|
|
|
|
|
|
Reacquisition of RAI uptake in RAI-refractory metastatic thyroid
cancers by pretreatment with the MEK inhibitor selumetinib (Abstract
#5509)
|
|
Presenter:
|
|
|
|
|
|
Alan L. Ho, MD, PhD
|
|
Date:
|
|
|
|
|
|
Monday, June 4, 2012, 1:00 – 1:15 p.m. EDT
|
|
|
|
MEK162
|
|
|
|
|
|
|
|
Title:
|
|
|
|
|
|
Efficacy and safety of oral MEK162 in patients with locally
advanced and unresectable or metastatic cutaneous melanoma
harboring BRAFV600 or NRAS mutations* (Abstract #8511)
|
|
Presenter:
|
|
|
|
|
|
Paolo A. Ascierto, MD
|
|
Date:
|
|
|
|
|
|
Monday, June 4, 2012, 4:45 – 5:00 p.m. EDT
|
|
|
|
|
|
|
|
|
The abstracts can be accessed through the ASCO website, http://abstract.asco.org/.
After June 4, 2012, the oral presentation slides will be available as
PDFs on Array's website at www.arraybiopharma.com.
*The abstract submitted for MEK162 does not incorporate data and new
findings generated since the time of submission in early 2012. The
latest and most up-to-date clinical data will be delivered during the
investigator’s presentation at the Annual Meeting itself, at the date
and time listed above.
In addition, the following scientific posters on selumetinib and
GDC-0068, an Akt inhibitor partnered with Genentech, will be presented
at the conference.
|
ASCO
Abstract
Number
|
|
|
|
|
ASCO Abstract Title
|
|
|
|
|
Presentation Date
and Time (EDT)
|
|
3529
|
|
|
|
|
Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor,
with AZD6244 (selumetinib), a MEK inhibitor, in patients with
advanced colorectal carcinoma (CRC)
|
|
|
|
|
Friday, June 1
2 - 6 pm
|
|
3020
|
|
|
|
|
A phase I, single-institution, open-label, dose escalation trial
with an expansion cohort evaluating the safety and tolerability of
AZD6244 and IMC-A12 in subjects with advanced solid malignancies
|
|
|
|
|
Saturday, June 2
2:15 - 6:15 pm
|
|
3021
|
|
|
|
|
A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or
mFOLFOX-6 (F) in patients (pts) with advanced solid tumors
|
|
|
|
|
Saturday, June 2
2:15 – 6:15 pm
|
|
8598
|
|
|
|
|
Pharmacodynamic activity of selumetinib to predict radiographic
response in advanced uveal melanoma
|
|
|
|
|
Sunday, June 3
9 am - 1 pm
|
|
3103
|
|
|
|
|
A phase I study of selumetinib (AZD6244/ARRY-142866) in combination
with cetuximab (cet) in refractory solid tumors and KRAS mutant
colorectal cancer (CRC)
|
|
|
|
|
Monday, June 4
9 am - 1 pm
|
|
4100
|
|
|
|
|
A phase I/II study of AZD6244 in combination with sorafenib (Nexavar
- Bayer/Onyx) in advanced hepatocellular carcinoma
|
|
|
|
|
Monday, June 4
9 am - 1 pm
|
|
TPS2616
|
|
|
|
|
A phase Ib/II study testing the safety and efficacy of combined
inhibition of the AKT/PI3K and AR signaling pathways in
castration-resistant prostate cancer: GDC-0068 or GDC-0980 with
abiraterone acetate versus abiraterone acetate
|
|
|
|
|
Monday, June 4
9 am - 1 pm
|
|
6582
|
|
|
|
|
Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in
advanced acute myeloid leukemia (AML)
|
|
|
|
|
Monday, June 4
2:15 - 6:15 pm
|
|
|
|
|
|
|
|
|
|
|
|
|
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small-molecule
drugs to treat patients afflicted with cancer and inflammatory diseases.
Array has four core proprietary clinical programs: ARRY-614 for
myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for
pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded
clinical programs including two MEK inhibitors in Phase 2: selumetinib
with AstraZeneca and MEK162 with Novartis. For more formation on Array,
please go to www.arraybiopharma.com.
Source: Array BioPharma
Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com
|
